Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Vakzine Projekt Management
Street 1: Mellendorferstr. 9
Street 2:
City: Hannover
Province:
Post Code: 30625
Country: Germany
Phone: 495111699080
Organization Email: info@vakzine-manager.de
Web Site: http://www.vakzine-manager.de
Other Online Presence:

Focal Point Contact Information

Salutation: Dr
First Name: Leander
Last Name: Grode
Title: Director Business Development TB/Malaria
Email: grode@vakzine-manager.de
Phone:  

Alternate Focal Point Contact Information

Salutation: Dr.
First Name: Caroline
Last Name: Sauer
Title: Project Manager
Email: sauer@vakzine-manager.de
Phone:  

General Information

Board Constituency: Private sector
Is your organization legally registered in your country: No
If yes, please enter your registration number:
Organization Type - Primary: Private Sector
Organization Type - Secondary: Company
Organization Description:
VPM is a private vaccine and drug development company with a product portfolio that targets a market of more than €6 billion (USD 7.1 billion). VPM develops products for the treatment of prostate cancer and multiple sclerosis as well as for the prevention of various infectious diseases. VPM was founded in 2002 and is based in Hannover, Germany. The company is seeking industry and financial partners to accelerate product development.

Multiple Sclerosis
Soluferon®, a second generation ß-interferon with increased bioavailability is in preclinical development for treatment of multiple sclerosis

Tuberculosis
VPM1002 is a live recombinant vaccine against tuberculosis. It is currently in phase II clinical trial in South Africa.

Human Cytomegalo Virus
Preventive vaccine against human cytomegalo virus in preclinical development

 
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Research and Development

Other Organization Information

Total number of staff in your organization: 6 - 10
Number of full-time staff who are directly involved with TB: 1 - 5
Number of part-time staff who are directly involved with TB: 1 - 5
Number of volunteers who are directly involved with TB: 100 +
 
How did you hear about the Stop TB Partnership: Attendance at a TB related event
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: No
Please tell us how your organization is contributing to your country's national TB control plan:
VPM develops a BCG replacement vaccine.
 

Geographical Reach

Which country is your headquarters located in: Germany
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Germany
India
South Africa

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

New TB Vaccines:
VPM develops a new recombiant TB vaccine. A prime vaccine to replace BCG.

Declaration

Declaration of interests:
VPM is a private vaccine and drug development company with a product portfolio. VPM develops products for the treatment of prostate cancer and multiple sclerosis as well as for the prevention of TB and HCMV. VPM was founded in 2002 and is based in Hannover, Germany. The company is seeking industry and financial partners to accelerate product development.


Prostate Cancer
A clinical phase I/II trial has successfully been completed with an allogeneic prostate cancer vaccine

Multiple Sclerosis
Soluferon®, a second generation ß-interferon with increased bioavailability is in preclinical development for treatment of multiple sclerosis

Tuberculosis
VPM1002 is a live recombinant vaccine against tuberculosis. It is currently in phase II clinical trial.


Human Cytomegalo Virus
Preventive vaccine against human cytomegalo virus in preclinical development


Application date:  
Last updated: February 25, 2015